Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein BorghaeiScott N GettingerEverett E VokesLaura Q M ChowMarco Angelo BurgioJavier De Castro CarpeñoAdam PluzanskiOscar ArrietaOsvaldo Arén FronteraRita ChiariCharles ButtsJoanna Wójcik-TomaszewskaBruno CoudertMarina Chiara GarassinoNeal ReadyEnriqueta Felip FontMiriam Alonso GarcíaDavid M WaterhouseManuel DómineFabrice BarlesiScott AntoniaMarkus WohlleberDavid E GerberGrzegorz CzyzewiczDavid R SpigelLucio CrinoWilfried Enst Erich EberhardtAng LiSathiya MarimuthuJulie BrahmerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
At 5 years, nivolumab continued to demonstrate a survival benefit versus docetaxel, exhibiting a five-fold increase in OS rate, with no new safety signals. These data represent the first report of 5-year outcomes from randomized phase III trials of a programmed death-1 inhibitor in previously treated, advanced NSCLC.